Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medicinova (MNOV) Shares Outstanding (Diluted Average) (2021 - 2025)

Medicinova (MNOV) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $49.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) changed N/A to $49.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $49.1 million, a N/A change, with the full-year FY2025 number at $49.1 million, changed N/A from a year prior.
  • Shares Outstanding (Diluted Average) was $49.1 million for Q4 2025 at Medicinova, roughly flat from $49.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $49.1 million in Q4 2025 to a low of $48.6 million in Q4 2021.
  • A 5-year average of $49.0 million and a median of $49.0 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 0.5% in 2022, then changed 0.0% in 2024.
  • Medicinova's Shares Outstanding (Diluted Average) stood at $48.6 million in 2021, then grew by 0.92% to $49.0 million in 2022, then grew by 0.0% to $49.0 million in 2023, then changed by 0.0% to $49.0 million in 2024, then increased by 0.04% to $49.1 million in 2025.
  • Per Business Quant, the three most recent readings for MNOV's Shares Outstanding (Diluted Average) are $49.1 million (Q4 2025), $49.0 million (Q3 2025), and $49.0 million (Q2 2025).